To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.

This bill requires the FDA to disclose whether a generic drug's inactive ingredients match those in the brand-name reference drug. It mandates that, upon request from a generic drug applicant, the FDA must confirm if the drugs are "qualitatively and quantitatively the same" in inactive ingredients or specify which ingredients differ and by how much. The policy directly affects generic drug manufacturers seeking FDA approval for their products. This change increases transparency in the drug approval process by providing clear, specific information to applicants about ingredient equivalence.